This inventor holds 1 USPTO granted patent. Top assignee: Coulter Corporation. Active years: 2001.
Company Filing History:
Years Active: 2001
Title: R L Ceriani: Innovator in Monoclonal Antibody Development
Introduction
R L Ceriani is a notable inventor based in Lafayette, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has implications for cancer diagnostics and treatment, showcasing the intersection of innovation and healthcare.
Latest Patents
R L Ceriani holds a patent for a hybridoma and anti-KC-4 humanized monoclonal antibody. This innovative antibody comprises the variable regions of the light and heavy chains of the anti-KC-4 murine antibody. The light chain has 7 amino acids, while the heavy chain has 12 amino acids of the framework regions substituted with amino acids present in equivalent positions in antibodies of a species other than murine. The constant regions of this antibody are derived from a human antibody. The anti-KC-4 monoclonal antibody can be labeled and/or glycosylated and is presented as a composition with a carrier. It is utilized in diagnostic kits for cancer and in in vivo methods for imaging and treating primary or metastasized cancer, as well as in vitro diagnosis and ex vivo purging of neoplastic cells from biological fluids. The monoclonal antibody is encoded by RNAs and DNAs, and a hybrid vector carrying the nucleotides allows transfected cells to express the peptides.
Career Highlights
R L Ceriani is associated with Coulter Corporation, where he has contributed to advancements in medical technology. His work in developing the anti-KC-4 monoclonal antibody exemplifies his commitment to improving cancer diagnostics and treatment options.
Collaborations
Throughout his career, R L Ceriani has collaborated with notable colleagues, including Fernando Jose Rebelo Do Couto and J A Peterson. These collaborations have likely enriched his research and contributed to the success of his innovations.
Conclusion
R L Ceriani's contributions to the field of monoclonal antibodies represent a significant advancement in cancer diagnostics and treatment. His innovative work continues to impact the medical community positively.